Researchers Trial Inhaled Versions Of Oxford And Imperial COVID-19 Vaccine Candidates

Daniel Fowler
September 14, 2020

Dr. Anthony Fauci, the top infectious disease expert on the USA government's coronavirus task force, agreed on Wednesday that the temporary halting of the Phase-3 Oxford vaccine trial was "not uncommon". In fact, it has been reported this same vaccine trial was temporarily halted back in July after a subject was diagnosed with multiple sclerosis.

However, the latest note added, "AstraZeneca and the University of Oxford, as the trial sponsor, can not disclose further medical information". New platforms are providing the life sciences industry with an opportunity to improve the efficiency of clinical trials and reduce costs while remaining compliant and reducing risk.

The coronavirus vaccine could be administered via an inhaler, after Imperial College London launched a trial to test the effectiveness of delivering a candidate directly into the lungs.

As global vaccine companies and academic institutions race the clock to deliver a safe Covid-19 vaccine, all eyes are on India that makes 60% of the world's vaccines.

Close on the heels of the AZ statement, Serum Institute of India said, "Once (the) DCGI (Drug Controller General of India) gives us the permission to restart the trials in India, we will resume the trials".

"I think one would have to say that we're on the edge of losing control", Mark Walport, the British government's former chief scientific adviser, told BBC radio.

Koeman delighted with Messi's first minutes
Barcelona went into meltdown when Messi announced he had made up his mind to leave following a hugely disappointing end to last season.

Though the vaccine candidate had yet to clear Phase Three clinical trials, the Kremlin claimed it had already been approved for civilian use.

AstraZeneca, a UK-based biopharma giant, had announced on Tuesday that the phase 3 testing of its COVID-19 vaccine being developed by it with Oxford University has been put on hold due to a suspected serious adverse reaction in a participant in the United Kingdom.

Charlotte Summers, lecturer in intensive care medicine at Cambridge University, welcomed the resumption of the Oxford trial and said the researchers had shown their commitment "to putting safety at the heart of their development program". In addition to this, SII can also cooperate with the Gamaleya Research Institute in Russian Federation to manufacture the Sputnik vaccine for COVID-19 treatment.

Italy's health minister, Roberto Speranza, welcomed the resumption of the vaccine trial, but warned that prudence was still necessary.

British scientists are beginning a small study comparing how two experimental coronavirus vaccines might work when they are inhaled by people instead of being injected. "In the meantime, the key continues to be our behavior".

Other reports by

Discuss This Article